Concord Healthcare Group Co., Ltd. Class H (HK:2453)
:2453
Want to see HK:2453 full AI Analyst Report?
Top Page
Concord Healthcare Group Co., Ltd. Class H
(2453)
Select Model
Select Model
Rating:51Neutral
Price Target:
HK$1.50
▼(-18.03% Downside)
Action:Upgraded
Date:04/18/26
The score is held back primarily by weak financial performance—deep operating losses, negative operating/free cash flow, and elevated leverage—despite improving revenue and gross margin. Technicals provide some support in the near term with price above key shorter moving averages, but longer-term trend remains weak and momentum looks near-term stretched. Valuation is constrained by losses (negative P/E) and no stated dividend yield.
Positive Factors
Revenue rebound & improving gross margin
A 21% revenue rebound and a shift to a positive gross margin indicate the business can restore top-line growth and improve core unit economics. If sustained, improved margins reduce cash burn per unit sold and create a clearer path toward operating leverage and eventual profitability over several quarters.
Negative Factors
Deep and persistent operating losses
Very large negative EBIT and net margins indicate the company remains structurally loss-making. Such persistent operating losses erode retained capital, constrain reinvestment, and require ongoing funding or restructuring. Without sustained margin recovery, profitability remains an uncertain multi-quarter outcome.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound & improving gross margin
A 21% revenue rebound and a shift to a positive gross margin indicate the business can restore top-line growth and improve core unit economics. If sustained, improved margins reduce cash burn per unit sold and create a clearer path toward operating leverage and eventual profitability over several quarters.
Read all positive factors
Concord Healthcare Group Co., Ltd. Class H (2453) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.07B
Dividend YieldN/A
Average Volume (3M)590.21K
Price to Earnings (P/E)―
Beta (1Y)0.28
Revenue Growth18.62%
EPS Growth44.24%
CountryHK
Employees567
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.34
Shares Outstanding313,874,630
10 Day Avg. Volume440,520
30 Day Avg. Volume590,206
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.62
Price to Sales (P/S)2.55
P/FCF Ratio-4.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Concord Healthcare Group Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Concord Healthcare Group Co., Ltd. provides oncology healthcare service for cancer patients and medical institutions in China. It also offers oncology-related services, including sales and installing of medical equipment and software; management a...
How the Company Makes Money
null...
Concord Healthcare Group Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
20
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 448.02M | 388.31M | 538.65M | 472.17M | 470.50M |
| Gross Profit | 31.12M | -67.25M | -65.09M | -197.46M | -92.76M |
| EBITDA | -232.16M | -194.46M | -172.58M | -355.51M | -356.26M |
| Net Income | -249.96M | -443.22M | -373.09M | -541.40M | -816.59M |
Balance Sheet | |||||
| Total Assets | 5.79B | 5.91B | 5.24B | 6.08B | 6.66B |
| Cash, Cash Equivalents and Short-Term Investments | 319.01M | 337.12M | 49.23M | 136.06M | 136.09M |
| Total Debt | 3.09B | 3.21B | 2.64B | 2.85B | 2.48B |
| Total Liabilities | 3.76B | 4.01B | 3.37B | 3.84B | 8.08B |
| Stockholders Equity | 1.83B | 1.65B | 1.60B | 1.69B | -1.56B |
Cash Flow | |||||
| Free Cash Flow | -259.95M | -500.12M | 18.11M | -175.66M | -584.24M |
| Operating Cash Flow | -113.08M | -185.96M | 201.85M | -93.64M | 45.87M |
| Investing Cash Flow | 110.91M | -668.09M | -182.34M | -100.33M | -945.04M |
| Financing Cash Flow | 92.10M | 1.02B | -105.43M | 184.37M | 505.06M |
Concord Healthcare Group Co., Ltd. Class H Technical Analysis
Positive
1.83
Price Trends
1.40
Positive
1.61
Positive
3.02
Negative
Market Momentum
0.03
Negative
67.80
Neutral
96.10
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2453, the sentiment is Positive. The current price of 1.83 is above the 20-day moving average (MA) of 1.30, above the 50-day MA of 1.40, and below the 200-day MA of 3.02, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 67.80 is Neutral, neither overbought nor oversold. The STOCH value of 96.10 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2453.
Concord Healthcare Group Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | HK$1.49B | 10.51 | 5.64% | 1.20% | 1.75% | ― | |
60 Neutral | HK$1.03B | 39.67 | 1.27% | ― | ― | ― | |
56 Neutral | HK$478.15M | -10.63 | 27.04% | ― | 2.00% | ― | |
56 Neutral | HK$7.10B | -21.28 | 0.62% | ― | -9.81% | -72.56% | |
54 Neutral | HK$1.54B | 117.78 | 0.48% | 0.49% | -2.63% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$1.07B | -3.94 | -15.15% | ― | 18.62% | 44.24% |
* Healthcare Sector Average
HK:2453
Concord Healthcare Group Co., Ltd. Class H
1.36
-5.02
-78.68%
HK:3309
C-MER Eye Care Holdings Limited
1.21
-0.49
-28.82%
HK:3869
Hospital Corporation of China Ltd
3.46
-3.20
-48.05%
HK:3886
Town Health International Medical Group Ltd.
0.23
>-0.01
-2.98%
HK:6078
Hygeia Healthcare Holdings Co., Ltd.
11.55
-3.09
-21.11%
HK:6639
Arrail Group Ltd.
1.83
-0.28
-13.32%
Concord Healthcare Group Co., Ltd. Class H Corporate Events
Concord Healthcare Completes HK$68 Million Convertible Bond Issue Under General Mandate
May 13, 2026
Concord Healthcare Group has completed the placement of HK$68 million in convertible bonds under its general mandate, with all conditions under the placing and subscription agreement satisfied as of 13 May 2026. The bonds are convertible into H sh...
Concord Healthcare Reshuffles Board as Executive Director Resigns and Employee Director Joins
May 11, 2026
Concord Healthcare Group has announced the resignation of executive director Chang Liang, who is stepping down with immediate effect due to personal career planning, and has indicated that he has no disagreements with the board or issues requiring...
Concord Healthcare Sets Out Board Structure and Key Governance Committees
May 11, 2026
Concord Healthcare Group Co., Ltd., a PRC-incorporated and Hong Kong-listed healthcare company, has outlined the composition of its board, which includes executive, non-executive, independent non-executive and an employee director. The structure i...
Concord Healthcare Shareholders Back AGM Resolutions and New Executive Director
May 11, 2026
Concord Healthcare Group Co., Ltd. reported that its annual general meeting in Beijing on May 11, 2026, proceeded in line with PRC company law and its articles of association, with shareholders holding about 42% of issued shares in attendance. All...
Concord Healthcare to Raise HK$68 Million via Convertible Bonds for Debt Repayment and Working Capital
May 11, 2026
Concord Healthcare Group plans to issue HK$68 million of convertible bonds under its existing general mandate, with an initial conversion price of HK$1.70 per share and conversion shares ranking pari passu with existing stock. While the bonds them...
Concord Healthcare Expands Mayo Clinic Partnership Into Full-Cycle Health Services
Apr 22, 2026
Concord Healthcare Group has signed a new cooperation agreement with the Mayo Foundation for Medical Education and Research that broadens their existing oncology-focused partnership into comprehensive life-cycle health services. The expanded colla...
Concord Healthcare Calls 2026 AGM and Seeks Mandate for New Share Issuance
Apr 15, 2026
Concord Healthcare Group Co., Ltd. has called its annual general meeting for May 11, 2026 in Beijing to review and approve key matters for the financial year ended December 31, 2025. Shareholders will vote on the directors’ report, the 2025 ...
Concord Healthcare Wins Strong Shareholder Backing for 2026 Credit Line Plan
Apr 10, 2026
Concord Healthcare Group Co., Ltd. held its 2026 extraordinary general meeting in Beijing, with shareholders representing about 27.03% of the company’s issued share capital in attendance and all directors and supervisors present. The meeting...
Concord Healthcare Taps President Jiang Wei as Executive Director in Leadership Transition
Apr 8, 2026
Concord Healthcare Group has announced a planned leadership transition as long-serving executive director Ms. Fu Xiao tenders her resignation upon reaching retirement age, and moves into an advisory role. The company emphasized that Ms. Fu has no ...
Concord Healthcare Narrows Losses as Revenue Climbs and Gross Margin Turns Positive
Mar 27, 2026
Concord Healthcare Group Co., Ltd., a PRC-based hospital and medical services operator, reported notable top-line growth in 2025 as it continued to expand its healthcare service offerings. The company’s revenue rose to RMB459.9 million from ...
Concord Healthcare Calls April EGM to Approve 2026 Credit Line and Guarantees
Mar 18, 2026
Concord Healthcare Group Co., Ltd., a Hong Kong-listed healthcare services provider incorporated in the PRC, has convened an extraordinary general meeting for its shareholders. The company serves the Chinese medical market and is governed by a boa...
Concord Healthcare Seeks Shareholder Approval for RMB3.7 Billion Subsidiary Guarantees
Mar 18, 2026
Concord Healthcare Group plans to provide new financing guarantees of up to RMB3.7 billion to its subsidiaries over a 12‑month period, subject to shareholder approval at an upcoming extraordinary general meeting. The move is intended to supp...
Concord Healthcare Sets March 27 Board Meeting to Approve 2025 Results
Mar 17, 2026
Concord Healthcare Group Co., Ltd. has scheduled a board meeting for March 27, 2026 to review and approve its annual results for the financial year ended December 31, 2025. At the same meeting, the board will also consider whether to recommend a f...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.